Search results
Biogen (BIIB) to Buy HI-Bio to Expand Rare Disease Pipeline
Zacks via Yahoo Finance· 3 days agoHI-Bio has plans to advance felzartamab into phase III for all indications. HI-Bio has received...
SuVax™ and MarVax™ Thermostable Vaccine Platform to be Presented at the Vaccine Technology IX...
FOX 23 News Albany· 6 days agoSoligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an ...
Calliditas Q1 report, January - March 2024
FOX 59 Indianapolis· 4 days agoNet sales amounted to SEK 295.5 million, of which TARPEYO® net sales amounted to SEK 278.3 million, for the three months ended March 31, 2024. For the...
Biogen to acquire HI-Bio for up to $1.8 billion By Investing.com
Investing.com· 4 days agoHI-Bio's lead asset, felzartamab, is an anti-CD38 monoclonal antibody with Breakthrough Therapy...
Sobi North America Gets FDA Fast Track Designation for Rheumatic Disease Complication Treatment
Market Watch· 2 days agoThe Waltham, Mass.-based affiliate of Swedish Orphan Biovitrum said Friday that the U.S. Food and Drug Administration had granted the designation to emapalumab-lzsg ...
Cartesian (RNAC) Up as FDA Grants RMAT Tag to Descartes-08
Zacks· 4 days agoFree Report) announced that the FDA has granted the Regenerative Medicine Advanced Therapy (RMAT) designation to its lead pipeline candidate, Descartes-08, for the treatment ...
Larimar (LRMR) Up on Lifting of Partial Clinical Hold on FA Study
Zacks· 5 days agoFree Report) announced that the FDA has removed the partial clinical hold on its nomlabofusp (CTI-1601) clinical program following a review of the phase II dose exploration ...
How patient advocacy can lead to more successful and meaningful clinical trials
Clinical Trials Arena via Yahoo Finance· 7 days agoBut this is not an endpoint that the US Food and Drug Administration (FDA) considers as meaningful...
Q1 2024 Biomx Inc Earnings Call
Thomson Reuters StreetEvents via Yahoo Finance· 5 days agoIn January this year, we were granted Orphan Drug Designation by the FDA for BX004. More recently, in April, we presented positive safety ...
BrainStorm Cell Therapeutics to Present New Biomarker Data Suggesting ALS Patients May Benefit From...
FOX 59 Indianapolis· 7 days agoThe Company will share the data with an international audience of patient advocacy groups, physicians, research organizations, industry representatives, key thought leaders and decision makers ...